Report Back From SABCS 2024: What’s the Latest in MBC
Welcome to our Season 10 opening episode! Today we’re discussing some of the big updates in metastatic breast cancer research from the 2024 San Antonio Breast Cancer Symposium (SABCS). Joining us today is Dr. Debu Tripathy, breast oncologist at The University of Texas MD Anderson Cancer Center who will break down into understandable terms some of the most impactful findings shared at SABCS, from advances in endocrine therapy and HER2-targeted treatments to exciting developments in PI3K inhibition and nausea control.
PI(3)King the Right Target
PI(3)King the right target after CDK4/6 inhibitors fail patients is an exciting area of research and FDA approval. Now that there are multiple options approved by the FDA and more to come, patients have more treatment choices. Join host Abigail Johnston as she interviews 2 patients who give us their perspective on these advances, as well as a doctor whose scientific research has led the way identifying PIK3CA mutations as a cancer genomic biomarker.